Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3312 Combination Therapies in Advanced Solid Tumors
NCT04720976Phase 2Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitneprotafib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Mar 2021; status: completed.
02
Drugs
sitneprotafib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04720976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720976.